Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Ludotadipep in mCRPC
NCT05579184Phase 2Active, not recruiting
- Sponsor
- FutureChem Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ludotadipep in metastatic castration-resistant prostate cancer (mCRPC), sponsored by FutureChem Co., Ltd. Primary endpoint: Prostate-Specific Antigen Response Rate up to 48 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
Ludotadipep
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05579184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579184.